Combination chemotherapy using intravenous nedaplatin (254-S) and intraarterial cisplatin (CDDP) with transcatheter arterial embolization (TAE) for a patient with uterine cervical cancer: a case report.

Abstract	A 45-year-old Japanese woman with a bulky (75 x 40 mm) stage 2a uterine cervical cancer was treated with 87 mg (50 mg/m2) of nedaplatin (254-S) intravenously and 120 mg (70 mg/m2) of cisplatin (CDDP) intraarterially with transcatheter arterial embolization (TAE). She received three courses of this combination chemotherapy and showed a complete response, as confirmed by magnetic resonance imaging. A radical hysterectomy was performed and the pathological findings revealed the absence of carcinoma cells. This type of combination chemotherapy seems to be effective for the treatment of locally advanced uterine cervical cancer.
Authors	S Adachi, N Yamasaki, T Ogasawara, Y Takayasu, T Takemura, K Koyama
Journal	Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 27 Issue 6 Pg. 442-4 (Dec 1997) ISSN: 0368-2811 [Print] England
PMID	9438011 (Publication Type: Case Reports, Journal Article)
Chemical References	Organoplatinum Compounds nedaplatin Cisplatin
Topics	Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Carcinoma, Squamous Cell (pathology, therapy) Cisplatin (administration & dosage) Combined Modality Therapy Embolization, Therapeutic Female Humans Hysterectomy Infusions, Intra-Arterial Infusions, Intravenous Middle Aged Organoplatinum Compounds (administration & dosage) Remission Induction Uterine Cervical Neoplasms (pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!